- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos.333-203040,333-210810,333-211512,333-213412,333-214843,333-216883 and333-228576 on FormS-8 and Registration Nos.333-209336,333-211511,333-216882,333-223134 and333-225284 on FormF-3 of our reports dated April 2, 2020, relating to the consolidated financial statements of Ascendis Pharma A/S and subsidiaries (the “Company”) (which report expresses an unqualified opinion and includes an explanatory paragraph regarding the Company’s change in its method of accounting for leases from January 1, 2019 due to the adoption of International Financial Reporting Standard 16 Leases), and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form20-F of Ascendis Pharma A/S for the year ended December 31, 2019.
Deloitte Statsautoriseret Revisionspartnerselskab
CVR no. 33963556
/s/ Sumit Sudan | /s/ Lars Hansen | |||
State Authorised Public Accountant | State Authorised Public Accountant |
Copenhagen, Denmark
April 2, 2020